| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -1,606 | 153,104 | -1,388 | -2,667 |
| Acquired in-process research and development | NaN | 0 | NaN | NaN |
| Depreciation and amortization | NaN | 0 | 0 | 0 |
| Gain on sale of dismutase mimetics assets | NaN | 3,500 | NaN | NaN |
| Share-based compensation expense | 78 | 92 | 91 | 227 |
| Gain on extinguishment of debt | NaN | 151,049 | NaN | NaN |
| Write-off of acquired intangible asset | NaN | 0 | 0 | NaN |
| Loss on disposal of property and equipment | NaN | 0 | 0 | NaN |
| Write-off of goodwill | NaN | 0 | 0 | NaN |
| Deferred tax benefit | NaN | 0 | 0 | NaN |
| Change in fair value of warrants | 0 | 0 | 0 | -294 |
| Prepaid expenses and other current assets | -157 | 292 | -289 | -360 |
| Other liabilities | NaN | 0 | 0 | 0 |
| Other assets | 0 | 0 | 0 | 1 |
| Accounts payable | 434 | -169 | 232 | -1,073 |
| Accrued expense | 62 | 216 | 19 | -246 |
| Cash used in operating activities | -875 | -1,598 | -757 | -3,694 |
| Cash paid for acquisition of nova | NaN | 0 | NaN | NaN |
| Proceeds from sale of property and equipment | NaN | 0 | 0 | NaN |
| Proceeds from sale of dismutase mimetics asset | NaN | 3,500 | NaN | NaN |
| Cash provided by investing activities | NaN | 3,500 | 0 | NaN |
| Proceeds from the sale of common stock in private placement | NaN | NaN | 0 | 635 |
| Proceeds from the sale of common stock and common stock warrants in private placement, net of issuance costs | 0 | 635 | NaN | NaN |
| Cash provided by financing activities | 0 | 0 | 0 | 635 |
| Net decrease in cash and cash equivalents | -875 | 1,902 | -757 | -3,059 |
| Cash and cash equivalents at beginning of period | 6,375 | 4,473 | 8,289 | NaN |
| Cash and cash equivalents at end of period | 5,500 | 6,375 | 4,473 | NaN |
Galera Therapeutics, Inc. (GRTX)
Galera Therapeutics, Inc. (GRTX)